Topiramate
Brand names: Qudexy Xr, Topiramate Er, Eprontia, Topamax, Topiramate, Trokendi Xr
At a glance
- Medicare prescriptions, 2024
- 2,668,319
- Medicare drug cost
- $69.8M
- Average cost per prescription
- $26.14
- Clinicians who prescribed it
- 78,074
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
QUDEXY XR is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut Syndrome in patients 2 years of age and older Preventive treatment of migraine in patients 12 years of age and older
From the FDA-approved prescribing information (label dated September 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Neurology 21.6%
- Family Medicine 19.9%
- Nurse Practitioners 17.8%
- Internal Medicine 13.6%
- Psychiatry 6.9%
- Physician Assistants 6.8%
- Psychiatric Nurse Practitioners 5.5%
- Pain Medicine 1.9%
- Geriatric Medicine 0.8%
- General Practice 0.7%
- Physical Medicine & Rehabilitation (PM&R) 0.7%
- Endocrinology & Diabetes 0.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 4% from 2019 to 2024.
Biggest change by state since 2019
- South Dakota +27%
- Puerto Rico +25%
- Iowa +24%
- Kansas +18%
- Montana +18%
- California (smallest change) −8%
- Nevada (smallest change) −6%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
A-S Medication Solutions
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white round tablet, 7 mm | ZD 15 |
Ascend Laboratories, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | yellow capsule, 14 mm | TOPER 25 |
| 50 mg | orange capsule, 16 mm | TOPER 50 |
| 100 mg | blue capsule, 19 mm | TOPER 100 |
| 200 mg | blue capsule, 24 mm | TOPER 200 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | white round tablet, 6 mm | E 22 |
Upsher-Smith Laboratories, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | gray capsule, 7 mm | UPSHER SMITH 25MG |
| 50 mg | gray capsule, 8 mm | UPSHER SMITH 50MG |
| 100 mg | gray capsule, 10 mm | UPSHER SMITH 100MG |
| 150 mg | gray capsule, 11 mm | UPSHER SMITH 150MG |
| 200 mg | gray capsule, 12 mm | UPSHER SMITH 200MG |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Dec 2023 · Azurity Pharmaceuticals, Inc. · Class III
Failed Impurities/Degradation Specifications: Out of specification Impurity C (4,5-desisopropylidene topiramate) result observed during routine stability testing at 18 months. - Oct 2021 · Unichem Pharmaceuticals USA Inc · Class III
Discoloration
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.